日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy

潜在生物标志物与接受帕博利珠单抗或化疗治疗的转移性三阴性乳腺癌临床结局的关联

期刊:NPJ Breast Cancer
影响因子:7.6
doi:10.1038/s41523-025-00814-y
Cortes, Javier; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Lee, Keun Seok; Schmid, Peter; Tamura, Kenji; Testa, Laura; Ohtani, Shoichiro; Harbeck, Nadia; Loi, Sherene; Salgado, Roberto; Karantza, Vassiliki; Mejia, Jaime; Cristescu, Razvan; Loboda, Andrey; Nebozhyn, Michael; Jelinic, Petar; Huang, Lingkang; Winer, Eric P
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies

晚期胃癌的基因组图谱：来自 KEYNOTE-059、KEYNOTE-061 和 KEYNOTE-062 研究的分析

期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO-24-00456
Janjigian, Yelena Y; Cecchini, Michael; Shitara, Kohei; Enzinger, Peter C; Wainberg, Zev A; Chau, Ian; Satoh, Taroh; Lee, Jeeyun; Nebozhyn, Michael; Loboda, Andrey; Kobie, Julie; Vajdi, Amir; Shih, Chie-Schin; Cristescu, Razvan; Cao, Z Alexander
胃癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study

高危早期三阴性乳腺癌患者新辅助帕博利珠单抗联合化疗疗效的分子决定因素：一项开放标签、多队列 1b 期 KEYNOTE-173 研究的探索性分析

期刊:Breast Cancer Research
影响因子:5.6
doi:10.1186/s13058-024-01946-y
Dent, Rebecca; Cortés, Javier; Park, Yeon Hee; Muñoz-Couselo, Eva; Kim, Sung-Bae; Sohn, Joohyuk; Im, Seock-Ah; Holgado, Esther; Foukakis, Theodoros; Kümmel, Sherko; Yearley, Jennifer; Wang, Anran; Nebozhyn, Michael; Huang, Lingkang; Cristescu, Razvan; Jelinic, Petar; Karantza, Vassiliki; Schmid, Peter
肿瘤
肿瘤免疫
乳腺癌
发表日期：2025
文献求助 收藏

Erratum: Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies

勘误：晚期胃癌的基因组图谱：来自 KEYNOTE-059、KEYNOTE-061 和 KEYNOTE-062 研究的分析

期刊:Jco Precision Oncology
影响因子:5.6
doi:10.1200/PO-25-00266
Janjigian, Yelena Y; Cecchini, Michael; Shitara, Kohei; Enzinger, Peter C; Wainberg, Zev A; Chau, Ian; Satoh, Taroh; Lee, Jeeyun; Nebozhyn, Michael; Loboda, Andrey; Kobie, Julie; Vajdi, Amir; Shih, Chie-Schin; Cristescu, Razvan; Cao, Z Alexander
胃癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Prevalence of Homologous Recombination Repair Mutations and Association with Clinical Outcomes in Patients with Solid Tumors: A Study Using the AACR Project GENIE Dataset

同源重组修复突变的患病率及其与实体瘤患者临床结局的关联：一项基于AACR GENIE项目数据集的研究

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers17040577
Shao, Changxia; Zhou, Heng; Chen, Cai; Dettman, Elisha J; Ren, Yixin; Cristescu, Razvan; Gozman, Alexander; Jin, Fan
发表日期：2025
文献求助 收藏

Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]

更正“组织肿瘤突变负荷和突变状态与帕博利珠单抗联合化疗与单纯化疗治疗转移性非小细胞肺癌的临床结果的关联”[JTO临床与研究报告 第4卷 第1期：100431]

期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2025.100892
Garassino, Marina C; Gadgeel, Shirish; Novello, Silvia; Halmos, Balazs; Felip, Enriqueta; Speranza, Giovanna; Hui, Rina; Garon, Edward B; Horinouchi, Hidehito; Sugawara, Shunichi; Rodriguez-Abreu, Delvys; Reck, Martin; Cristescu, Razvan; Aurora-Garg, Deepti; Loboda, Andrey; Lunceford, Jared; Kobie, Julie; Ayers, Mark; Piperdi, Bilal; Pietanza, M Catherine; Paz-Ares, Luis
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial

帕博利珠单抗治疗晚期尿路上皮癌：KEYNOTE-361 III期试验的ctDNA生物标志物探索性分析

期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-024-03091-7
Powles, Thomas; Chang, Yen-Hwa; Yamamoto, Yoshiaki; Munoz, Jose; Reyes-Cosmelli, Felipe; Peer, Avivit; Cohen, Graham; Yu, Evan Y; Lorch, Anja; Bavle, Abhishek; Homet Moreno, Blanca; Markensohn, Julia; Edmondson, Mackenzie; Chen, Cai; Cristescu, Razvan; Peña, Carol; Lunceford, Jared; Gunduz, Seyda
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

评估乐伐替尼联合帕博利珠单抗治疗晚期子宫内膜癌患者的潜在生物标志物：111/KEYNOTE-146 研究结果

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2023-007929
Makker, Vicky; Taylor, Matthew H; Aghajanian, Carol; Cohn, Allen L; Brose, Marcia S; Simone, Christopher Di; Cao, Zhu Alexander; Suttner, Leah; Loboda, Andrey; Cristescu, Razvan; Jelinic, Petar; Orlowski, Robert; Dutta, Lea; Matsui, Junji; Dutcus, Corina E; Minoshima, Yukinori; Messing, Mark J
肿瘤
子宫内膜癌
肿瘤免疫
发表日期：2024
文献求助 收藏

Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma

肿瘤突变负荷和PD-L1与帕博利珠单抗联合或不联合化疗治疗晚期尿路上皮癌疗效的相关性

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-3518
Fléchon, Aude; Morales-Barrera, Rafael; Powles, Thomas; Alva, Ajjai; Özgüroğlu, Mustafa; Csöszi, Tibor; Loriot, Yohann; Rodriguez-Vida, Alejo; Géczi, Lajos; Cheng, Susanna Y; Fradet, Yves; Oudard, Stéphane; Vulsteke, Christof; Gunduz, Seyda; Mamtani, Ronac; Yu, Evan Y; Montesa Pino, Alvaro; Anido, Urbano; Sendur, Mehmet A N; Gravis, Gwenaelle; Révész, János; Kostorov, Vladimir; Huillard, Olivier; Ma, Junshui; Rajasagi, Mohini; Vajdi, Amir; Lunceford, Jared; Cristescu, Razvan; Imai, Kentaro; Homet Moreno, Blanca; Matsubara, Nobuaki
PD-L1
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases

晚期前列腺癌中同源重组修复突变的真实世界患病率：两个临床基因组数据库的分析

期刊:Prostate Cancer and Prostatic Diseases
影响因子:5.8
doi:10.1038/s41391-023-00764-1
Shui, Irene M; Burcu, Mehmet; Shao, Changxia; Chen, Cai; Liao, Chi-Yin; Jiang, Shan; Cristescu, Razvan; Parikh, Ravi B
肿瘤
前列腺癌
肿瘤免疫
发表日期：2024
文献求助 收藏